本季度信息
深圳市海普瑞药业集团股份有限公司发布2025年第三季度财报，报告期营收13.77亿元，同比增长11.82%。扣除非经常性损益后净利润为1.26亿元，同比增长26.54%。管理层指出，去年同期投资收益较高所带来的基数差异，是本期投资收益同比走低的原因之一。
报告期内，研发费用投入1.76亿元，同比增长35.28%，主要系本阶段在研项目增加所致；财务费用为-1.57亿元，同比大幅下降289.66%。从前九个月累计数据看，经营活动现金流净额达到14.41亿元，同比下滑19.60%，主要系销售回款与采购支付节奏变化所致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.